Compare WMS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMS | CORT |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 9.7B |
| IPO Year | 2014 | 2001 |
| Metric | WMS | CORT |
|---|---|---|
| Price | $130.98 | $113.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $180.63 | $96.50 |
| AVG Volume (30 Days) | 656.6K | ★ 805.4K |
| Earning Date | 05-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.19 | 0.09 |
| Revenue | ★ $3,050,376,000.00 | $761,407,000.00 |
| Revenue This Year | $5.23 | $26.08 |
| Revenue Next Year | $12.79 | $26.98 |
| P/E Ratio | ★ $61.98 | $1,259.44 |
| Revenue Growth | 5.03 | ★ 12.79 |
| 52 Week Low | $128.03 | $28.66 |
| 52 Week High | $179.32 | $126.38 |
| Indicator | WMS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 34.25 | 51.71 |
| Support Level | $129.64 | $77.73 |
| Resistance Level | $155.66 | $122.21 |
| Average True Range (ATR) | 4.18 | 4.04 |
| MACD | -1.32 | -1.68 |
| Stochastic Oscillator | 0.93 | 15.22 |
Advanced Drainage Systems Inc designs, manufactures and markets water management solutions in the stormwater and onsite wastewater industries, providing superior drainage solutions for use in the construction and agriculture markets. The company's products are used across a broad range of end markets and applications, including non-residential, residential, infrastructure and agriculture applications. It has two reportable segments: Stormwater and Wastewater. It derives the majority of revenue from the Stormwater segment, which manufactures and markets thermoplastic corrugated pipe and complementary products, including single wall pipe, N-12 HDPE pipe, polypropylene pipe, StormTech, Nyloplast, Inserta Tee, water quality filters and structures, and NDS channel drains, and access boxes.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.